Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2654

Sigma-Aldrich

Telaprevir

≥90% (HPLC)

Synonym(s):

2-(2-(2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-(1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, LY-570310, VX-950

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C36H53N7O6
Molecular Weight:
679.85
MDL number:
MFCD11616089
UNSPSC Code:
12352107
NACRES:
NA.77

Assay

≥90% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

[H][C@@]1([C@@]2(CCC1)[H])CN(C([C@@H](NC([C@@H](NC(C3=NC=CN=C3)=O)C4CCCCC4)=O)C(C)(C)C)=O)[C@@H]2C(N[C@H](C(C(NC5CC5)=O)=O)CCC)=O

Biochem/physiol Actions

Telaprevir is a potent, selective and orally active hepatitis C virus (HCV) NS3.4A serine protease inhibitor. Telaprevir also inhibits chymotrypsin, chymase, elastase, and cathepsins F, K, L, S, and V in vitro

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361fd

Hazard Classifications

Repr. 2

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Robert B Perni et al.
Antimicrobial agents and chemotherapy, 50(3), 899-909 (2006-02-24)
VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC50] = 354 nM) and in human fetal
Gema Méndez-Lagares et al.
Journal of immunology (Baltimore, Md. : 1950), 200(3), 1124-1132 (2017-12-22)
The contribution of the host immune system to the efficacy of new anti-hepatitis C virus (HCV) drugs is unclear. We undertook a longitudinal prospective study of 33 individuals with chronic HCV treated with combination pegylated IFN-α, ribavirin, and telaprevir/boceprevir. We

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service